___

• 1. Maynard, JE. Hepatitis B. global importance and need for control. Vaccine 1990; 8 Suppl: S18-23.
• 2. Hézode C, Pawlotsky JM. Chronic hepatitis B: antiviral treatment guidelines. Rev Prat 2010;60:751-8.
• 3. Perry CM, Simpson D. Tenofovir disoproxil fumarate in chronic hepatitis B. Drugs 2009; 12:2245-56.
• 4. Lampertico P, Colombo M. HBeAg-negative chronic hepatitis B: Why do I treat my patients with nucleos (t)ide analogues. Liver Int 2009;29:130-2. doi:10.1111/j.14783231.2008.01931.x
• 5. Wong SN, Lok ASF. Tenofovir disoproxil fumarate: Role in hepatitis B treatment. Hepatology. 2006;44:309-13.
• 6. Heathcote E, Marcellin P, Buti M, et al. Three –year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011; 140:132-43. doi:10.1053/j.gastro.2010.10.011
• 7. Heathcote J, George J, Gordon S, et al. Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-positive chronic hepatitis B: Week 72 TDF data and week 24 adefovir dipivoxil switch data ( study 103) (abstract). J Hepatol 2008;48:S32.
• 8. Marcellin P, Jacobson I, Habersetzer F, et al. Tenofovir disoproxil fumarate ( TDF ) for the treatment of HBeAg-negative chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data ( study 102) (abstract). J Hepatol 2008;48:S26.
• 9. Van der Eijk AA, Hansen BE, Niesters HG, et al. Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants. J Viral Hepat 2005 ;12:364-72. doi: 10.1111/ j.1365-2893.2005.00620.
• 10. Ozdemir FT, Duman D, Ertem D, et al. Determination of hepatitis B genotypes in patients with chronic hepatitis B virus infection in Turkey. Turk J Gastroenterol 2005;16:183-7.